Birmingham VA Joins Psilocybin Depression Trial

The Birmingham VA Hospital is one of five sites testing psilocybin for veterans with treatment-resistant major depression.

Updated on Nov. 12, 2026 in Health

Photograph of an empty reclining armchair in a calm, plainly furnished clinical room, with soft daylight from a tall window beside a low potted plant.
The Birmingham VA Hospital is one of five sites testing psilocybin for veterans with treatment-resistant major depression in a trial enrolling 240 participants over four years. AI Illustration. Upload story photo >

Live Poll

Should the federal government expand research into psilocybin for treating depression?

Birmingham VA Hospital has been named one of five test sites for the PIVOT trial, which is studying psilocybin as a treatment for treatment-resistant major depressive disorder in veterans, with and without PTSD. The study plans to enroll 240 veterans over four years.

Why it matters

The trial comes as the federal government pushes to expand research into new treatments for serious mental illness. Psilocybin has not been approved by the FDA for routine clinical treatment of depression or PTSD, so any future use within the VA system would depend on that approval.

The trial plans to enroll 240 veterans across five sites over four years, comparing two psilocybin doses. Outcomes have not been reported, and it is not yet known whether the approach will prove effective.

The players

Birmingham VA Hospital

A Veterans Affairs medical facility serving central and northern Alabama, one of five sites selected to test psilocybin for veterans with treatment-resistant depression.

ClinicalTrials.gov

The U.S. National Library of Medicine's public registry of clinical studies, where the PIVOT trial is registered under identifier NCT07226232.

The details

Participants receive psilocybin in a controlled clinical setting using pharmaceutical-grade drugs under FDA-reviewed safety protocols, with psychological support and monitoring throughout. Screening includes both mental and physical evaluations.

Timeline

  1. The trial is planned to run over four years, enrolling 240 veterans across five test sites.

Big Picture

The PIVOT trial is one concrete example of research activity that President Donald Trump's executive order on serious mental illness treatment aims to accelerate. Psilocybin remains unapproved by the FDA for depression or PTSD, so the trial tests a therapy still outside routine clinical practice.

Any future psilocybin treatment for veterans would depend on FDA approval, so the trial does not change current care options. Veterans considering the study would need to meet screening criteria covering both mental and physical health.

The takeaway

Psilocybin trials at VA sites are still in the testing phase, and veterans with treatment-resistant depression should rely on approved care while results are awaited. Interested readers can track the study through its public registry entry.

Further reading

For related coverage of treatment research and access, see Mental Health news in Birmingham.

More information

Details of the PIVOT trial are listed in the ClinicalTrials.gov study registry under identifier NCT07226232.

Source note: This article includes information reported by WHNT.

Live Poll

Should the federal government expand research into psilocybin for treating depression?